In our previous study, we labeled the clinically available anti-EGFR antibody cetuximab with 64Cu and intraperitoneally (ip) administered it to an orthotopic xenograft mouse model of small resectable (<1 cm) pancreatic cancer. Here, EGFR is linked to pancreatic neoplasm.